🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Harnessing Moravec’s Paradox in Health Care: A New Era of Collaborative Intelligence | NEJM AI ai.nejm.org/doi/full/10.10…

We're bringing NASA+ to @Netflix! Starting this summer, Netflix audiences will be able to stream rocket launches, spacewalks, and other major live events on the platform. Read more about how we're working to bring NASA's work to a global audience: go.nasa.gov/40wCJdY

Very interesting, NEJM cases are the most costly & complicated, hence published. Key issues comes to practicality: if using the model for decision support increases reimbursement / lowers liability (cost share w model), adoption will skyrocket. Until then, nice benchmarking tool.

Everyone: “AI is so smart, we don’t need humans anymore, just vibe prescribing bots” Models managing real world patients:

Bemarituzumab Plus Chemotherapy Improved Overall Survival in People With FGFR2b Overexpression GC Compared to Chemotherapy Alone amgen.com/newsroom/press…

What actually happens when someone’s diagnosed with cancer. A thread:

We’re Massive Bio. We help people with cancer find clinical trials that actually match their case—based on cancer type, stage, and biomarker results.

Arturo LoAIza-Bonilla, MD MSEd discusses the potential of disitamab vedotin, toripalimab, and chemotherapy/trastuzumab in first-line treatment. #gicsm #ASCO25 | St. Luke's University Health Network hubs.li/Q03vff960

Per Wired, Meta is poaching researchers with packages up to $300M over 4 years (with 1st yr comp >$100m), and that they've made 10 such offers to people at OpenAI. For context, this is roughly what Meta's execs get paid per year: • CFO: $23.5M • COO: $25.5M • CTO: $23.5M •

#ESMOGI25 🚨: Claudin 18.2 bispecific plus nivo/FOLFOX in Claudin 18.2 + #UpperGI cancers! 🔑 points: - ORR 71%, 6 mth PFS 72.9% - Response regardless of PDL-1 CPS - broader defn of Claudin + makes this relevant to larger population - no DLTs noted. #ESMOAmbassadors ESMO - Eur. Oncology

WATCH: Arturo Loaiza-Bonilla, MD, MSEd, (Arturo LoAIza-Bonilla, MD MSEd) discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the #ASCO25. #gicsm hubs.li/Q03vvvmX0

BREAKING: An incredible "gigantic jet" – an extremely-rare type of upper-atmospheric lightning – was photographed from the International Space Station on Friday morning. This is the clearest photo we have EVER seen of a gigantic jet from above. Nichole Rhea Ayers is a major in

CLDN18.2 Antibody-Drug Conjugate (ADC) Progress in GI Cancers: Pipeline Overview Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #GICancer #GastrointestinalCancer #ADCs #Oncology #CancerResearch #CancerData

WATCH: Arturo Loaiza-Bonilla, MD, MSEd, (Arturo LoAIza-Bonilla, MD MSEd) discusses 5-year data from the phase 3 CheckMate 577 trial, presented at #ASCO25. #gicsm hubs.li/Q03vGWdC0

☀️ Mainiu's automatic car awnings are becoming popular in China to avoid cars becoming boiling hot when parked outside during the summer.

I think people are underestimating the impact AI will have in health care by *supercharging* clinicians and *overestimating* the impact it will have in replacing them

Happy moments with family and dear friends ❤️ 🇨🇴

Gene therapy cures genetic deafness for the first time - in kids AND adults. One injection restored hearing in 10 people aged 1.5 to 24 years, reports Nature Medicine Here's how 🧵

Arturo Loaiza-Bonilla, MD, MSEd, (Arturo LoAIza-Bonilla, MD MSEd) explains the background and findings of the phase 3 DESTINY-Gastric04 trial. #gicsm | St. Luke's University Health Network hubs.li/Q03w5d1b0

QS ranks MIT the world’s No. 1 university for 2025-26. This is the 14th year in a row MIT has received this distinction. news.mit.edu/2025/qs-ranks-…